Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2021-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司独立董事关于第十届董事会第九次会议相关事项的独立意见
Regulatory Filings
2021-04-22 Chinese
经世律师事务所关于金宇生物技术股份有限公司回购注销2020年限制性股票激励计划部分限制性股票相关事项之法律意见书
Regulatory Filings
2021-04-22 Chinese
金宇生物技术股份有限公司第十届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company, detailing the approval of various reports including the 2020 Annual Report, 2021 Q1 Report, profit distribution plan, internal control evaluation, and other supervisory matters. It includes voting results and confirms compliance with laws and regulations. The document does not contain the full reports themselves but rather the Supervisory Board's review and approval of these reports and related matters. The length is short (1857 characters), and it is an announcement of resolutions rather than the reports themselves. This fits best under Regulatory Filings (RNS) as it is a formal announcement of supervisory board decisions and approvals, not the full annual or quarterly reports.
2021-04-22 Chinese
金宇生物技术股份有限公司二〇二〇年度内部控制审计报告
Regulatory Filings
2021-04-22 Chinese
金宇生物技术股份有限公司二〇二〇年度审计报告
Regulatory Filings
2021-04-22 Chinese
金宇生物技术股份有限公司关于回购注销部分限制性股票（暨减少注册资本）通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a notification from a company about the repurchase and cancellation of restricted shares, which leads to a reduction in registered capital. It includes details about the board meeting resolutions, the number of shares repurchased and cancelled, the impact on registered capital, and instructions for creditors to claim debts or request guarantees. The document is not a financial report, earnings release, or management discussion. It is a formal announcement related to a capital change due to share repurchase and cancellation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS.
2021-04-22 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.